- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07645703
MS and Health Cohort (MS-Health)
Disability Progression in Multiple Sclerosis: Determinants, Pathophysiology, and Global Health Impact
This study aims to identify clinical, biological, imaging, and environmental factors that predict the progression and severity of Multiple Sclerosis (MS). We will establish a prospective, highly phenotyped cohort of patients diagnosed with MS according to the 2024 criteria, regardless of disease form or stage.
We hypothesize that combining neurological, vascular, metabolic, neuropsychological, environmental, and imaging data (from the central nervous system and the eye) will improve the identification of markers associated with MS progression. This integrative approach will help clarify the respective roles of inflammation, vascular dysfunction, myelin repair, and neurodegeneration in disability accumulation.
The study will also evaluate the impact of MS, disability, and treatments on patients' physical, mental, and social health, as defined by the World Health Organization (WHO). These results are expected to support personalized patient management and identify modifiable risk factors to reduce disability and inform future therapeutic strategies.
The primary objective is to identify factors that worsen neurological disability in MS patients, including disease-related, comorbidity, and environmental factors. The main outcome measure is time to confirmed disability accumulation (CDA), defined as an increase in the EDSS (Expanded Disability Status Scale) score confirmed after at least 3 months.
This single-center, 5-year prospective cohort study will be conducted at Hôpital Fondation Adolphe de Rothschild (Paris, France), with annual visits. A linkage with national health data (SNDS) will be established for both MS patients and a matched control group (5:1 ratio).
Additional research procedures include:
Ophthalmologic exams (OCT, angio-OCT, fundus photography, pupillometry) at baseline, year 1, 3, and 5.
Brain MRI with additional non-contrast research sequences (annual).
Clinical assessments including arterial stiffness and hearing tests.
Blood sampling (up to 40 mL) for biomarker analyses and long-term biobanking (25 years).
Lumbar puncture if clinically indicated at baseline (with extra samples for research).
Physical activity and circadian rhythm monitoring using a wrist accelerometer for 9 consecutive days.
Standardized questionnaires assessing quality of life, education, and social/professional impact.
Inclusion criteria:
Age ≥ 18 years
Diagnosis of MS according to 2024 criteria
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age ≥ 18 years.
- Multiple sclerosis defined according to the 2024 criteria.
- Participant affiliated with or beneficiary of a social security system, Universal - -- Health Coverage (CMU), or any equivalent healthcare coverage scheme.
- Written informed consent.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Progressive disease with a life expectancy of less than one year.
- Inability to undergo MRI
- Person refusing to be informed of any clinically significant finding concerning their health discovered during participation in the study.
- Patient impairment making participation in the study or understanding of the - information provided difficult or impossible.
- Person under legal protection measures (guardianship, curatorship, or judicial protection).
- Person deprived of liberty by judicial or administrative decision.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Confirmed disability accumulation (CDA)
Délai: 5 years
|
The primary endpoint will be time to confirmed disability accumulation.
Confirmed disability accumulation (CDA) will be defined as an increase in the Expanded Disability Status Scale (EDSS) score of ≥1.5 points if the previous EDSS score was 0; ≥1.0 point if the previous EDSS score ranged from 1.0 to 5.5; and ≥0.5 point if the previous EDSS score was greater than 5.5 (19).
The increase must be confirmed after a minimum of 3 months.
Each patient may experience one or several episodes of neurological disability worsening during follow-up.
|
5 years
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- APX_2025_9
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .